IVIG for Infection Prevention After CAR-T-Cell Therapy

Exclusion Criteria

• •Primary congenital selective IgA deficiency
• •Prior serious adverse event/s related to intravenous immune globulin (IVIG) administration
• •Known serious allergy to any component of IVIG
• •Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study or interfere with the patient's ability to participate for the full duration of the study or would put the patient at undue risk as judged by the investigator, such that it is not in the best interest of the patient to participate in this study
• •SUBSEQUENT INFUSIONS: Ongoing symptoms of cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS) meeting criteria for grade 3 or higher
• •SUBSEQUENT INFUSIONS: Primary congenital selective IgA deficiency
• •SUBSEQUENT INFUSIONS: Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study or interfere with the patient's ability to participate for the full duration of the study or would put the patient at undue risk as judged by the Investigator, such that it is not in the best interest of the patient to participate in this study
• •SUBSEQUENT INFUSIONS: Receipt of additional therapy for persistence or relapse of the patient's primary malignancy
• •SUBSEQUENT INFUSIONS: Receipt of bone marrow transplant (allogeneic or autologous)
• •SUBSEQUENT INFUSIONS: Any serious adverse event (SAE), clinically significant adverse event (AE), severe laboratory abnormality, intercurrent illness, or other medical condition that indicates to the Investigator that continued participation is not in the best interest of the participant